"use strict";(self.webpackChunkBenStockTracker=self.webpackChunkBenStockTracker||[]).push([[1745],{1745:e=>{e.exports=JSON.parse('{"95303f78-9bfd-33a5-b79e-85b4a9e0288c":{"uuid":"95303f78-9bfd-33a5-b79e-85b4a9e0288c","title":"Senate Finance report says AbbVie shifted profit overseas to cut taxes","publisher":"Reuters","link":"https://finance.yahoo.com/news/senate-finance-report-says-abbvie-180205901.html","providerPublishTime":1657216925,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/kUh7f_Kp4WIIgJxdYo_xqg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/wSm7SEcv9Mc71So9ANBl5Q--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/a87e7048ccada000918e5d34547ddc71","width":800,"height":533,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/HPWkcYz7udItqEmTOjRe2Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/wSm7SEcv9Mc71So9ANBl5Q--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/a87e7048ccada000918e5d34547ddc71","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"cc8420fe-01f8-3e0b-85b4-85ff830fff37":{"uuid":"cc8420fe-01f8-3e0b-85b4-85ff830fff37","title":"Is AbbVie Stock A Buy As Humira Biosimilar Rivals Loom?","publisher":"Investor\'s Business Daily","link":"https://finance.yahoo.com/m/cc8420fe-01f8-3e0b-85b4-85ff830fff37/is-abbvie-stock-a-buy-as.html","providerPublishTime":1657211775,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/m5d.Smd693RMHHIXgMp5Pw--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/JHLtl__Lui2o0PmaQCfHxQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5a5a59904ea1192cc06eb982caacc0e2","width":1000,"height":563,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/o_.HlPSfHXegjFg37AN7ZA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/JHLtl__Lui2o0PmaQCfHxQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/5a5a59904ea1192cc06eb982caacc0e2","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","AGN","PFE"]},"71002e2a-1c9b-3556-87cc-347ab20de03e":{"uuid":"71002e2a-1c9b-3556-87cc-347ab20de03e","title":"4 High-Dividend Stocks Rise In Face Of Recession Freak-Out","publisher":"Investor\'s Business Daily","link":"https://finance.yahoo.com/m/71002e2a-1c9b-3556-87cc-347ab20de03e/4-high-dividend-stocks-rise.html","providerPublishTime":1657195207,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/Kpl2m98wy.Xky_gMCVle0A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/qvHAAdyB2KQtamXmL0e.EA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4944147fe1cad5dfa843e09e738d8cb0","width":1000,"height":563,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/xbq190HgdVkberqfxvgRnA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/qvHAAdyB2KQtamXmL0e.EA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/4944147fe1cad5dfa843e09e738d8cb0","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["SPGI","ABBV","CAG"]},"b3321fef-f056-3610-b073-961b446285e6":{"uuid":"b3321fef-f056-3610-b073-961b446285e6","title":"Senate Report Hits AbbVie\u2019s Bermuda Tax Structure for U.S. Humira Sales","publisher":"The Wall Street Journal","link":"https://finance.yahoo.com/m/b3321fef-f056-3610-b073-961b446285e6/senate-report-hits-abbvie%E2%80%99s.html","providerPublishTime":1657184400,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/a2mEeDeNQi4ZP48DATVCdw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/Z_lHiioJ0IoIjvFLELQjhA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/5231df6e92ba627ffab7c7898d571ee6","width":1280,"height":640,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/61gDhsTwWkJZWKeW7nsrxQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/Z_lHiioJ0IoIjvFLELQjhA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/5231df6e92ba627ffab7c7898d571ee6","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"a0a7f061-b4c2-3b33-93ff-4ee5a7df0939":{"uuid":"a0a7f061-b4c2-3b33-93ff-4ee5a7df0939","title":"Applied Molecular Shares Tumble After Disappointing Data From Mid-Stage Ulcerative Colitis Study","publisher":"Benzinga","link":"https://finance.yahoo.com/news/applied-molecular-shares-tumble-disappointing-125609288.html","providerPublishTime":1657112169,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/uw_9ZhQ2zx_uiNDOPNpajQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/OActccoEOL10.PqGwnUXrA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0aeb32b2528c9c9d82a0ebfc0bd46bad","width":600,"height":400,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/VMWIna_HdGN8HAjFBldfpw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/OActccoEOL10.PqGwnUXrA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/0aeb32b2528c9c9d82a0ebfc0bd46bad","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]},"8d9434e3-b6b7-3a04-87e4-51e5e69f436c":{"uuid":"8d9434e3-b6b7-3a04-87e4-51e5e69f436c","title":"These 5 Top Stocks Are Set to Outperform in a Recession","publisher":"Motley Fool","link":"https://finance.yahoo.com/m/8d9434e3-b6b7-3a04-87e4-51e5e69f436c/these-5-top-stocks-are-set-to.html","providerPublishTime":1657106520,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/Q9qLx_5iX7sWLMqCobHnUg--~B/aD04NzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/WiVjEgcV7HW9kXqEobj7uA--~B/aD04NzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8ee70757418fad5c69de0bd4e217ca69","width":1400,"height":873,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/Gx.U.1GLNfut4fG.UNY7_w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/WiVjEgcV7HW9kXqEobj7uA--~B/aD04NzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8ee70757418fad5c69de0bd4e217ca69","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["AMT","ABBV","PANW","ISRG"]},"c69dcafb-9967-3ee8-842f-74a1b95a5807":{"uuid":"c69dcafb-9967-3ee8-842f-74a1b95a5807","title":"AbbVie (ABBV) Gains But Lags Market: What You Should Know","publisher":"Zacks","link":"https://finance.yahoo.com/news/abbvie-abbv-gains-lags-market-214509647.html","providerPublishTime":1657057509,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/gS0nw.47qgAgvrgADz_fWQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0","width":900,"height":601,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/Ybt7Kr93VFMGfaWqBsqsmw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/w.ILboV799eZj6zbyZJ3SQ--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5ecaf2a9bf082a5f3a554e6526b34be0","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV","^GSPC"]},"58c7dbc0-e42f-3cf9-a05f-ada610b730f4":{"uuid":"58c7dbc0-e42f-3cf9-a05f-ada610b730f4","title":"This Blockbuster Drug from AbbVie Is Closer to Another Major Indication","publisher":"Motley Fool","link":"https://finance.yahoo.com/m/58c7dbc0-e42f-3cf9-a05f-ada610b730f4/this-blockbuster-drug-from.html","providerPublishTime":1657020600,"type":"STORY","thumbnail":{"resolutions":[{"url":"https://s.yimg.com/uu/api/res/1.2/jPtg44baL2B4uShCEfNXaA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/fkj_ahv78sweZPKU87JYwg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/21836605811fec94d2719c98c30f5487","width":1400,"height":933,"tag":"original"},{"url":"https://s.yimg.com/uu/api/res/1.2/BvVGf63TOAYA2bUR7deU4w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/fkj_ahv78sweZPKU87JYwg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/21836605811fec94d2719c98c30f5487","width":140,"height":140,"tag":"140x140"}]},"relatedTickers":["ABBV"]}}')}}]);